Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali.
Kassoum KayentaoAissata OngoibaAnne C PrestonSara A HealySafiatou DoumboDidier DoumtabeAbdrahamane TraoreHamadi TraoreAdama DjiguibaShanping LiMary E PetersonShinyi TelscherAzza H IdrisNeville K KisaluKevin CarltonLeonid SerebryannyySandeep NarpalaAdrian B McDermottMartin R GaudinskiSiriman TraoreHamidou CisseMamadou KeitaJeff SkinnerZonghui HuAmatigué ZéguiméAdama OuattaraM'Bouye DoucoureAmagana DoloAbdoulaye DjimdéBoubacar TraoreRobert A SederPeter D Cromptonnull nullPublished in: The New England journal of medicine (2022)
CIS43LS was protective against <i>P. falciparum</i> infection over a 6-month malaria season in Mali without evident safety concerns. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04329104.).